Condition (MeSH)
Purpura, Thrombotic Thrombocytopenic
ClinicalTrials.gov lists 65 trials for Purpura, Thrombotic Thrombocytopenic or a narrower condition beneath it. Takeda has the most among industry and government lead sponsors, with 6.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
65 of the 65 trials are tagged with Purpura, Thrombotic Thrombocytopenic itself; the rest are tagged with a narrower condition beneath it.
When did Purpura, Thrombotic Thrombocytopenic trials start? (22)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 1 |
| 2024 | 6 |
| 2023 | 3 |
| 2022 | 5 |
| 2021 | 5 |
| 2020 | 2 |
| 2019 | 3 |
| 2018 | 4 |
| 2017 | 3 |
Showing 10 of 22 earlier years.
No forecast is made for this condition: it averages 4.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Purpura, Thrombotic Thrombocytopenic trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 17 |
| Phase 2/3 | 2 |
| Phase 3 | 10 |
| Phase 4 | 2 |
| Not applicable | 3 |
| Observational | 28 |
| Expanded access | 1 |
How many Purpura, Thrombotic Thrombocytopenic trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 12 |
| Active, not recruiting | 4 |
| Completed | 21 |
| Approved for marketing | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Purpura, Thrombotic Thrombocytopenic trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Takeda | 6 |
| Octapharma | 3 |
| Sanofi | 3 |
| Ablynx, a Sanofi company | 2 |
| Archemix Corp. | 2 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Purpura, Thrombotic Thrombocytopenic? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Caplacizumab | 8 |
| RITUXIMAB | 7 |
| TAK-755 | 5 |
| Lusutrombopag | 2 |
| ARC1779 | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Plasma Exchange | 3 |
| Corticosteroids | 2 |
| EC Aspirin | 1 |
| Anti-CD20 antibody | 1 |
| Recombinant ADAMTS13 | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Purpura, Thrombotic Thrombocytopenic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Thrombotic thrombocytopenic purpura | 75 | 5 |
| Death | 44 | 1 |
| Thrombotic Thrombocytopenic Purpura | 19 | 1 |
| Thrombocytopenia | 6 | 4 |
| Epistaxis | 5 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Purpura, Thrombotic Thrombocytopenic? (92)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Characteristics and Management of Patients With Immune Thrombotic Thrombocytopenic Purpura Admitted to the Intensive Care Unit: A Multicenter Retrospective Analysis. | American journal of hematology | 2026 | Yes |
| Clinical Manifestations, Treatment Characteristics, and Clinical Outcomes in Patients with Immune Thrombotic Thrombocytopenic Purpura (iTTP) in a Real-World Setting: An Interim Analysis of the Turkish iTTP Registry | Turkish journal of haematology : official journal of Turkish Society of Haematology | 2025 | Yes |
| Immune-mediated thrombotic thrombocytopenic purpura with systemic lupus erythematosus: clinical features and outcome. | Lupus science & medicine | 2025 | Yes |
| Tailored treatment of acute immune-mediated thrombotic thrombocytopenic purpura. | Hematology. American Society of Hematology. Education Program | 2025 | Yes |
| Management and follow-up of pregnancy-onset thrombotic thrombocytopenic purpura: the French experience. | Blood advances | 2024 | Yes |
Showing 5 of 92 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Thrombotic thrombocytopenic purpura | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Thrombotic thrombocytopenic purpura | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Thrombotic thrombocytopenic purpura | Annual incidence | 1-9 / 1 000 000 | Worldwide | Not stated | Unspecified |
| Thrombotic thrombocytopenic purpura | Annual incidence | 1-9 / 1 000 000 | Worldwide | Not stated | Exact |
| Thrombotic thrombocytopenic purpura | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Thrombotic thrombocytopenic purpura | 54057 | Exact | Orphadata Science knowledge files, Product 1 |
| Thrombotic thrombocytopenic purpura | 54057 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.